Navigation Links
ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:10/30/2008

inuing its growth to become the leading niche ophthalmic pharmaceutical company in the U.S. For additional information regarding ISTA, please visit ISTA Pharmaceuticals'

website at http://www.istavision.com.

Any statements contained in this press release which refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to reporting preliminary results from Xibrom 0.09% once-daily Phase III studies in 2008, the filing of an sNDA for Xibrom 0.09% as a once-daily treatment for the pain and inflammation associated with cataract surgery in 2009, the filing of an NDA for Bepreve in 2008, the completion of additional T-Pred studies later this year or in early 2009, the announcement of ecabet sodium preliminary Phase II top-line results, ISTA's expectation of bringing a new product to market every 12 to 18 months and becoming the leading niche ophthalmic pharmaceutical company are forward-looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and r
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
2. Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
3. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
4. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
5. Watson Pharmaceuticals Reports Third Quarter 2008 Results
6. Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
7. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
10. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
11. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... gluttons. We have long known that they monopolize large ... some tumor cells are also characterized by a series ... in an ordered set. Researchers are calling this behavior ... EPFL, Etienne Meylan,s research team was able to demonstrate ... mesenchymal behavior result from the same mechanism, at ...
(Date:7/28/2014)... July 29, 2014 The ... Situ Hybridization, Digital pathology & Workflow, Special ... Prostate Cancer, Non Small Cell Lung Cancer ... (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research ... Americas, Europe, BRIC, Japan & RoW) - ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A lush green ... playtime during the summer. However, the summer heat, lack of ... to become brown, weak and unhealthy. The Grounds Guys recommends ... Grow, Mow a lawn once a week and set the ... normal. This protects the grass roots from heat and allows ...
(Date:7/28/2014)... UHY LLP, a member of the ... UHY International Business – Issue 29. This bi-annual publication ... most current business challenges and key issues faced by ... the following topics:, , Key industry ... over the next five years? Where are growth opportunities ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2
... Keynote Afternoon Session on Legal, Regulatory and,Policy Issues, ... healthcare in the United States?, That,s a ... national conference,Personalized Medicine: Promises and Challenges, sponsored by ... and the Food and Drug Law,Institute (FDLI), June ...
... launching a communications revolution, cell phones are talking up ... use of telecommunications technology to provide medical diagnosis and ... thousands of miles apart. Researchers in the United States ... system that uses ordinary cell phone cameras to collect ...
... joins The Libby Ross Foundation to ... unveil celebrity-designed yoga bags, NEW YORK, May 5 ... Ross Foundation to help empower women,battling breast cancer through the charity,s ... has joined the,cause to raise funds for this unique program by ...
... Access to Educational Programming to Promote Stroke Awareness ... Prevention during Stroke Awareness ... and,Comcast have partnered to raise awareness and understanding of the ... through Comcast,s ON DEMAND service. Throughout the month of May,in ...
... a leading healthcare,communications network, announced that Michel Nakache has ... will join Doug Burcin and Donna,Murphy as a Worldwide ... "We,re thrilled to have Michel back at Euro ... a perfect fit for our growing agency,",said Burcin. "Michel,s ...
... new organic 0% fat Greek yogurt flavors to ... satisfy consumers, hungry demands, ... organic yogurt-maker, is expanding the flavor offerings of its,organic, authentically ... yogurts join the Oikos Organic line of,0% fat favorites, Vanilla ...
Cached Medicine News:Health News:AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008 2Health News:AAAS, FDLI Sponsor Landmark Meeting on Personalized Medicine June 20, 2008 3Health News:Talking up a new role for cell phones in telemedicine 2Health News:Celebrity Mothers and Daughters Including Miley and Trish Cyrus Join Swarovski to Support Breast Cancer Survivors 2Health News:The American Heart Association and Comcast Team Up to Strike Out Stroke 2Health News:The American Heart Association and Comcast Team Up to Strike Out Stroke 3Health News:Michel Nakache Returns to Euro RSCG Life as Worldwide Managing Partner 2Health News:Oikos Organic Greek Yogurt Ventures into the Land of Milk and Honey ... and Blueberry! 2Health News:Oikos Organic Greek Yogurt Ventures into the Land of Milk and Honey ... and Blueberry! 3
(Date:7/28/2014)... 28, 2014 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... status of the KB001-A development program, including an update ... KB001-A Collaboration Update KaloBios announced ... to regain all rights to KaloBios, KB001-A program. Under ... in 2010 has been terminated. Under that collaboration agreement, ...
(Date:7/28/2014)...  Serco Inc., a provider of professional, technology, ... awarded a re-compete contract to support the Navy ... Medical Systems.  Serco will provide deployable medical systems ... healthcare to meet warfighter and humanitarian requirements in ... five year contract has a one-year base period ...
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... In response to a report recently issued by the ... rising death toll from prescription painkiller overdose, Reckitt Benckiser ... to learn more about the disease of addiction, available ... www.TurnToHelp.com . The new CDC ...
... International, Inc. (NYSE: VRX ) (TSX: VRX) ... to the role of Executive Vice President and Chief ... Valeant, which is expected to be December 1, 2011. ... he was the chief operating officer for the Investment ...
Cached Medicine Technology:New Report Puts Spotlight on Epidemic of Painkiller Abuse and Need for Patient Education and Resources 2Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 2Valeant Pharmaceuticals Appoints Howard B. Schiller as Chief Financial Officer 3
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
Medicine Products: